Nykode Therapeutics (OB:NYKD) - Prezzo delle azioni, notizie e analisi

NYKD Panoramica delle azioni

Nykode Therapeutics AS, una società biofarmaceutica in fase clinica, scopre e sviluppa nuove immunoterapie.

NYKD analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 23.32% all'anno

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 17.8% all'anno per i prossimi 3 anni

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Gli azionisti sono stati diluiti nell'ultimo anno

Nykode Therapeutics AS Concorrenti

ArcticZymes Technologies

OB:AZT

NOK 858.0m

Hofseth BioCare

OB:HBC

NOK 661.8m

Lytix Biopharma

OB:LYTIX

NOK 302.6m

PCI Biotech Holding

OB:PCIB

NOK 64.1m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Nykode Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	NOK 5.29
Massimo di 52 settimane	NOK 21.62
Minimo di 52 settimane	NOK 4.37
Beta	1.34
1Variazione di 1 mese	-3.64%
Variazione a 3 mesi	-63.52%
Variazione di 1 anno	-73.01%
3Variazione a 3 anni	-91.84%
Variazione a 5 anni	n/a
Variazione dall'IPO	-73.28%

Notizie e aggiornamenti recenti

We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

Aug 05

Recent updates

We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

Aug 05

Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 02

Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)

Jan 22

We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth

Aug 20

Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business

Apr 06

Could The Vaccibody AS (OB:VACC) Ownership Structure Tell Us Something Useful?

Jan 25

Rendimenti per gli azionisti

	NYKD	NO Biotechs	NO Mercato
7D	3.9%	-5.0%	-1.3%
1Y	-73.0%	-58.2%	2.2%

Ritorno vs Industria: NYKD ha avuto una performance inferiore rispetto al Norwegian Biotechs che ha registrato un rendimento -54.1 % nell'ultimo anno.

Rendimento vs Mercato: NYKD ha avuto una performance inferiore al mercato Norwegian che ha registrato un rendimento 5.4 % nell'ultimo anno.

Volatilità dei prezzi

Is NYKD's price volatile compared to industry and market?
NYKD volatility
NYKD Average Weekly Movement	16.8%
Biotechs Industry Average Movement	10.8%
Market Average Movement	4.9%
10% most volatile stocks in NO Market	10.6%
10% least volatile stocks in NO Market	2.7%

Prezzo delle azioni stabile: Il prezzo delle azioni di NYKD è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di NYKD è aumentata da 10% a 15% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2006	179	Michael Engsig	nykode.com

Nykode Therapeutics AS, azienda biofarmaceutica in fase clinica, scopre e sviluppa nuove immunoterapie. L'azienda sviluppa vaccini per il trattamento del cancro e delle malattie infettive. I suoi principali prodotti candidati includono VB10

Nykode Therapeutics AS Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Nykode Therapeutics con la sua capitalizzazione di mercato?
NYKD statistiche fondamentali
Capitalizzazione di mercato	NOK 1.73b
Guadagni(TTM)	-NOK 414.35m
Ricavi(TTM)	NOK 71.21m

24.3x

Rapporto P/S

-4.2x

Rapporto P/E

NYKD è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
NYKD Conto economico (TTM)
Ricavi	US$6.52m
Costo del fatturato	US$0
Profitto lordo	US$6.52m
Altre spese	US$44.43m
Guadagni	-US$37.91m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Nov 27, 2024

Utile per azione (EPS)	-0.12
Margine lordo	100.00%
Margine di profitto netto	-581.88%
Rapporto debito/patrimonio netto	0%

Come si è comportato NYKD nel lungo periodo?

Vedi performance storica e confronto

NYKD Panoramica delle azioni

Premi

Analisi del rischio

Nykode Therapeutics AS Concorrenti

OB:AZT

NOK 858.0m

OB:HBC

NOK 661.8m

OB:LYTIX

NOK 302.6m

OB:PCIB

NOK 64.1m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Consensus revenue estimates decrease by 19%

Price target decreased by 20% to kr29.13

Consensus revenue estimates decrease by 54%, EPS upgraded

Chairman of the Board recently bought kr283k worth of stock

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

Recent updates

Consensus revenue estimates decrease by 19%

Price target decreased by 20% to kr29.13

Consensus revenue estimates decrease by 54%, EPS upgraded

Chairman of the Board recently bought kr283k worth of stock

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

New minor risk - Share price stability

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting

Consensus revenue estimates decrease by 35%, EPS upgraded

Consensus revenue estimates increase by 37%, EPS downgraded

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

Director recently bought kr310k worth of stock

Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer

Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases

Price target decreased by 36% to kr43.00

Consensus EPS estimates upgraded to US$0.18 loss

Chief Executive Officer recently bought kr100k worth of stock

Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)

Nykode Therapeutics AS to Report Q4, 2024 Results on Feb 26, 2025

Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer

Third quarter 2023 earnings released: US$0.03 loss per share (vs US$0.05 loss in 3Q 2022)

New minor risk - Shareholder dilution

Nykode Therapeutics ASA Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer

Nykode Therapeutics ASA Announces Advances in Clinical Pipeline and Research

Nykode Therapeutics ASA Announces FDA Approval of IND for VB-C-04, a Trial of VB-C-04 in HPV16-Positive Cervical Cancer

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth

Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the Next Trial in Advanced Cervical Cancer

Nykode Therapeutics AS Announces Management Changes

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business

Full year 2022 earnings released: US$0.15 loss per share (vs US$0.033 loss in FY 2021)

Director exercised options and sold kr7.4m worth of stock

Nykode Therapeutics AS to Report Q3, 2023 Results on Nov 15, 2023

Nykode Expands Clinical Development Plan for Its Lead Cancer Vaccine Vb10.16 in Hpv16-Positive Cancers

Third quarter 2022 earnings released: US$0.05 loss per share (vs US$0.03 loss in 3Q 2021)

No independent directors

Nykode Therapeutics Presents Additional Efficacy Analysis in Phase 2 Study of VB10.16 in Combination with Atezolizumab in Advanced Cervical Cancer

Nykode Therapeutics ASA Announces Presentation of Positive Immunogenicity Results from Phase 1/2A Study of VB10.NEO

Nykode Therapeutics ASA Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate

Second quarter 2022 earnings released: US$0.03 loss per share (vs US$0.02 loss in 2Q 2021)

Nykode Therapeutics Announces Positive Interim Results in HPV+ Cervical Cancer Phase 2 Trial

Nykode Therapeutics AS Appoints Klaus Edvardsen as Chief Development Officer, Effective from July 1, 2022

Chairman of the Board recently bought kr321k worth of stock

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Nykode Therapeutics AS Appoints Elaine Sullivan and Anne Whitaker to the Board of Directors

Nykode Therapeutics AS Announces Positive Interim Results from Its Phase 2 Trial with VB10.16 in Combination with Immune Checkpoint Inhibitor Atezolizumab in Advanced Cervical Cancer

No independent directors

Nykode Therapeutics as Announces Presentation of Preclinical Data from Its Second Generation Vaccibody Vaccine Technology At 2022 American Association for Cancer Research (AACR) Annual Meeting

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Nykode Therapeutics Announces Completion of Patient Enrollment in Its Phase 2 Trial of Vb10.16 in Combination with Atezolizumab for the Treatment of Advanced Cervical Cancer

Investor sentiment deteriorated over the past week

Nykode Therapeutics AS Announces First Subject Dosed with Its T Cell Focused Next-Generation SARS-CoV-2 Vaccine Candidate